COMMUNIQUÉS West-GlobeNewswire

EssilorLuxottica: Publication of the 2024 Interim Financial Report
26/07/2024
Publication of the 2024 Interim Financial Report Paris, France (July 26, 2024 – 6:30 pm) – The Board of Directors of EssilorLuxottica met on July 25, 2024 to approve the condensed consolidated interim financial [...]
EssilorLuxottica: Mise à disposition du Rapport financier semestriel 2024
26/07/2024
Mise à disposition du Rapport financier semestriel 2024 Paris, France (26 juillet 2024 – 18h30) – Le Conseil d’administration d’EssilorLuxottica, qui s’est réuni le 25 juillet 2024, a arrêté les comptes consolidés [...]
eLabNext and ABI-LAB Announce Strategic Partnership to Foster Innovation in Life Sciences
26/07/2024
BOSTON, July 26, 2024 (GLOBE NEWSWIRE) -- eLabNext, a leading provider of digital lab management solutions, and ABI-LAB , a premier life sciences incubator located in Natick, MA, have announced a strategic alliance [...]
BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo
26/07/2024
July 26, 2024 News Release BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo ADLM 2024 Conference – Chicago, July 26, 2024 – BioPorto Diagnostics, a company specializing in in vitro [...]
Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab
26/07/2024
SHANGHAI, July 26, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
26/07/2024
NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (" Psyence Group ") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is [...]
Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency
26/07/2024
Southlake, TX, July 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”) , an artificial intelligence (AI)-powered medical technology [...]
Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting
26/07/2024
Boston (July 26, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, announced that its [...]
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
26/07/2024
Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospinal fluid (CSF) [...]
OneMedNet Announces $4.6 Million Private Placement
26/07/2024
Institutional investors include affiliates of Off the Chain Capital and Discovery Capital Management MINNEAPOLIS, July 26, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), [...]
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
26/07/2024
$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the warrants subject to shareholder approval Fundraise supports development of novel antibody PMN310 [...]
Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
26/07/2024
Presentation to feature Silo’s novel therapeutics for the underserved SARASOTA, FL, July 26, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical [...]
CHMP recommends RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of prior therapy
26/07/2024
Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, currently face a poor prognosis and limited treatment options after disease progression on osimertinib 1 ,2,3,4 In the [...]
TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million
26/07/2024
Scienture, Inc., a private branded and specialty pharmaceutical company, entered into a business combination with TRxADE Health Inc., in an all-stock transaction valued at $103 million. TAMPA, FL and COMMACK, NY, July [...]
Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024
26/07/2024
PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2024 financial results [...]
Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds
26/07/2024
PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that it has entered into a definitive agreement for the exercise [...]
Genetic Technologies Strategic Restructure Driving USA Sales Growth
26/07/2024
CHARLOTTE, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease and the parent [...]
GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis
26/07/2024
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients [...]
GENFIT : Avis positif du Comité des médicaments à usage humain (CHMP) pour l’Iqirvo® (élafibranor) d’Ipsen dans la Cholangite Biliaire Primitive
26/07/2024
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), 26 juillet 2024 - GENFIT (Nasdaq et Euronext : GNFT) , une société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie [...]

Pages